Bristol Settlement Over Vanlev Could Require Clinical Trial Disclosure
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed settlement would resolve class action suit alleging Bristol misled investors about safety problems with its failed investigational antihypertensive.
You may also be interested in...
GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.